Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19
Satoshi Iwata, Osamu Kobayashi, Kazuyoshi Kurashima, Yohei Doi, Hiroyuki Kunishima, Masaharu Shinkai, Kenji Tsushima, Masaya Yamato, Akira Kano, Makoto Hibino, Takahiro Yamatake, Tsutomu Sakurai, Takashi Ogura
Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2023.10.010
Introduction: Favipiravir terminates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Accordingly, early administration of favipiravir to SARS-CoV-2-infected coronavirus disease 2019 (COVID-19) patients may be expected to suppress disease progression. Methods: A randomized double-blind placebo-controlled trial was conducted to demonstrate efficacy of favipiravir in reducing disease progression in patients with mild COVID-19. The participants were unvaccinated patients with comorbidities and at risk of progression to severe disease. Patients were enrolled within 72 hours of disease onset and randomized to receive either favipiravir (1800 mg/dose on Day 1 followed by 800 mg/dose) or matching placebo twice daily for 10 days. The primary endpoint was the proportion of patients requiring oxygen therapy within 28 days of randomization.
Results: The trial was discontinued after enrolling 84 patients due to slower than anticipated enrollment caused by rapid uptake of SARS-CoV-2-vaccines and the emergence of the Omicron variant. Results from the 84 patients demonstrated no significant difference in all clinical outcomes. In post-hoc analyses, favipiravir treatment showed higher efficacy in patients within 48 hours of onset. No deaths or severe adverse events were documented in the favipiravir group. Plasma concentrations of favipiravir from Day 2 onward were maintained above 40 μg/mL.
Conclusions: Conducting clinical trials for pathogens like SARS-CoV-2 that rapidly accumulate mutations leading to altered disease characteristics carries significant risks unless it can be done in a short period. Therefore, it would be important to prepare the comprehensive clinical trial platform that can appropriately and promptly evaluate drugs even under a pandemic.
Declaration of competing interest TY and TS are employees of the sponsor. SI reports consulting fees from Fujifilm Toyama Chemical, and Meiji Seika Pharma; lecture fees from Pfizer, and Gilead Sciences. YD reports consulting fees from Fujifilm Toyama Chemical, Shionogi, GSK, Gilead Sciences, and Moderna. MS reports consulting fees from Genova Inc., Shionogi, Ono Pharmaceutical, AstraZeneca, Pfizer, Chugai, and Fujitsu; lecture fees from Fujifilm Toyama Chemical. OK, HK, and KT report consulting fee from Fujifilm Toyama Chemical. KK, MY, AK, and TO report lecture fee from Fujifilm Toyama Chemical. J o u r n a l P r e -p r o o f
References
Chiba, Kiso, Nakajima, Iida, Maemura et al., Coadministration of favipiravir and the remdesivir metabolite GS-441524 effectively reduces SARS-CoV-2 replication in the lungs of the syrian hamster model, mBio,
doi:10.1128/mbio.03044-21Doi, Ishihara, Banno, Ando, Kondo et al., Favipiravir for symptomatic COVID-19: A nationwide observational cohort study, J Infect Chemother,
doi:10.1016/j.jiac.2022.10.008Driouich, Cochin, Lingas, Moureau, Touret et al., Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model, Nat Commun,
doi:10.1038/s41467-021-21992-wGowen, Wong, Jung, Smee, Morrey et al., Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models, Antiviral Res,
doi:10.1016/j.antiviral.2009.10.015Kaptein, Jacobs, Langendries, Seldeslachts, Horst et al., -p r o o f al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2014441117Killingley, Mann, Kalinova, Boyers, Goonawardane et al., Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults, Nat Med,
doi:10.1038/s41591-022-01780-9Madhi, Kwatra, Myers, Jassat, Dhar et al., Population immunity and Covid-19 severity with Omicron variant in South Africa, N Engl J Med. J o u r n a l P r e -p r o o f,
doi:10.1056/NEJMoa2119658Noor, Islam, Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis, J Community Health,
doi:10.1007/s10900-020-00920-xOestereich, Lüdtke, Wurr, Rieger, Muñoz-Fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res,
doi:10.1016/j.antiviral.2014.02.014Oestereich, Rieger, Lüdtke, Ruibal, Wurr et al., Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever, J Infect Dis,
doi:10.1093/infdis/jiv522Ogata, Tanaka, Irie, Hirayama, Takahashi, Shorter incubation period among unvaccinated Delta variant Coronavirus Disease 2019 Patients in Japan, Int J Environ Res Public Health,
doi:10.3390/ijerph19031127Ohashi, Watashi, Saso, Shionoya, Iwanami et al., Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment, iScience,
doi:10.1016/j.isci.2021.102367Shinkai, Tsushima, Tanaka, Hagiwara, Tarumoto et al., Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: A randomized, phase III clinical trial, Infect Dis Ther,
doi:10.1007/s40121-021-00517-4Singh, Khera, Chugh, Khera, Chugh, Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis, BMJ Open,
doi:10.1136/bmjopen-2020-048416Singh, Singh, Singh, Misra, An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2022.102396Sirijatuphat, Manosuthi, Niyomnaitham, Owen, Copeland et al., Early treatment of favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study, Emerg Microbes Infect,
doi:10.1080/22221751.2022.2117092Sissoko, Laouenan, Folkesson, Lebing, Beavogui et al., Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): A historically controlled, single-arm proof-of-concept trial in Guinea, PLoS Med,
doi:10.1371/journal.pmed.1001967Tanaka, Ogata, Shibata, Nagai, Takahashi et al., Shorter incubation period among COVID-19 cases with the BA.1 Omicron variant, Int J Environ Res Public Health,
doi:10.3390/ijerph19106330Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-tomoderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int J Infect Dis,
doi:10.1016/j.ijid.2020.11.142Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0Yotsuyanagi, Ohmagari, Doi, Imamura, Sonoyama et al., A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part), Medicine,
doi:10.1097/MD.0000000000033024
